← Back to Home

Old blood pressure drug telmisartan could open broader cancer uses for PARP inhibitors

A Dartmouth Cancer Center study reports that the commonly used blood pressure drug telmisartan can enhance the anticancer effect of olaparib in preclinical models and bring immune responses into the fight; the real answer still awaits ongoing human trials.

By SURL BioNews

Some challenges in cancer treatment are not that a drug is completely ineffective, but that it works only against some tumors. The PARP inhibitor olaparib is a representative example of this kind of precision drug: it can exploit defects in cancer cells' DNA repair to deliver a lethal blow, but for that reason it has often been limited to tumors with BRCA mutations or homologous recombination repair deficiency. If an oral drug long used for hypertension could make more tumors sensitive to this kind of treatment, its significance would be more than "repurposing an old drug"; it could potentially redraw the boundaries of existing therapies.

According to research released by Dartmouth Cancer Center and cited by ScienceDaily, the research team found that the angiotensin II receptor blocker telmisartan can significantly enhance the cancer-cell-killing activity of olaparib. The study has been published in the Journal for ImmunoTherapy of Cancer, with a focus on how telmisartan improves the efficacy of olaparib in tumors where homologous recombination repair function remains intact.

This point is especially important. PARP inhibitors have historically been best at attacking cancers whose DNA repair systems already have weaknesses; however, many patients' tumors do not have this typical defect, and even if they respond initially, they may gradually develop drug resistance. The research team's preclinical experiments showed that when telmisartan and olaparib are used together, they not only increase DNA damage inside cancer cells, but also raise type I interferon production, making it easier for the immune system to recognize and attack tumors.

The report also noted that this enhancing effect is not shared by all blood pressure drugs of the same class. After comparing different ARB drugs, the researchers considered telmisartan's effect in this model to be relatively unique; at the same time, it also reduced PD-L1 levels in tumor cells. PD-L1 is a molecule many cancer cells use to evade immune detection. If this effect can be reproduced in humans, the combination therapy may affect not only DNA repair, but also the tumor immune microenvironment.

Clinical translation has already begun. The Dartmouth team said two human trials are currently evaluating telmisartan in combination with olaparib: one in men with metastatic castration-resistant prostate cancer, and the other enrolling patients with platinum-resistant ovarian cancer. The source material mentioned that the first participant in the prostate cancer trial had an "exceptional response," but a single case cannot represent overall efficacy, nor is it enough to determine which patients are most likely to benefit.

This is also where the current interpretation of the study most needs restraint. Telmisartan's safety, oral convenience, and existing clinical use do make it easier than a completely new molecule to enter testing as part of cancer combination therapy; however, cancer patients' medication backgrounds, blood pressure status, tumor types, and immune environments are all more complex. The immune activation and anticancer effects seen in preclinical models still must be confirmed through clinical trials with sufficient enrollment, clear endpoints, and safety monitoring.

If subsequent trials support it, this approach could extend PARP inhibitors in two ways: first, by giving tumors without typical DNA repair defects a chance to benefit, and second, by serving as a combination strategy to overcome drug resistance. Until then, however, it is not a medication recommendation to try on one's own, but a hypothesis that is moving from mechanistic research toward clinical validation. The familiar face of an old drug does not automatically shorten the road required to prove that a cancer therapy is effective.

References

  1. ScienceDaily Top Health